Browse
Submit Data
Databases
API
Help

Dataset Information

5 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)

ABSTRACT: The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

DISEASE(S): Colorectal Cancer Stage Iv,Msi-high,Microsatellite Instability,Microsatellite Instability-high (msi-h) Or Mismatch Repair Deficient(dmmr) Stage Iv Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms,Microsatellite Instability-high (msi-h) Or Mismatch Repair Deficient (dmmr) Stage Iv Colorectal Cancer

PROVIDER: 2378213 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

scRNAseq of orthotopic mismatch repair deficient (dMMR) or chromosomally instable (CIN) colorectal cancer

Project description:Colorectal cancers (CRCs) deficient in DNA mismatch repair (dMMR) contain abundant CD8+ tumor infiltrating lymphocytes (TILs) responding to the abundant neoantigens from their unstable genomes. Priming of such tumor-targeted TILs first requires recruitment of CD8+ T cells into the tumors, implying that this is an essential prerequisite of successful dMMR anti-tumor immunity. We have discovered that selective recruitment and activation of systemic CD8+ T cells into dMMR CRCs strictly depends on overexpression of CCL5 and CXCL10 due to endogenous activation of cGAS/STING and IFN signaling by damaged DNA. TIL infiltration into orthotopic dMMR CRCs is neoantigen-independent and followed by induction of a resident memory-like phenotype key to the anti-tumor response. CCL5 and CXCL10 could be upregulated by common chemotherapies in all CRCs, indicating that facilitating CD8+ T cell recruitment underlies their efficacy. Induction of CCL5 and CXCL10 thus represents a tractable therapeutic strategy to induce TIL recruitment into CRCs where local priming can be maximized even in neoantigen-poor CRCs.

2021-07-19 | GSE178706 | GEO

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Project description:In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator’s choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy.

| 2199120 | ecrin-mdr-crc

scRNAseq of orthotopic mismatch repair deficient (dMMR) or chromosomally instable (CIN) colorectal cancer

Project description:scRNAseq of orthotopic mismatch repair deficient (dMMR) or chromosomally instable (CIN) colorectal cancer

| PRJNA740039 | ENA

IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Project description:The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or metastatic colorectal cancer.

| 2329228 | ecrin-mdr-crc

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability.

Project description: Not available

| S-EPMC7697596 | biostudies-literature

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Project description:The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.

| 2310012 | ecrin-mdr-crc

Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.

Project description: Not available

| S-EPMC7337255 | biostudies-literature

Extreme intratumor heterogeneity and driver evolution in mismatch repair deficient gastro-esophageal cancer

Project description:Mismatch repair deficient (dMMR) gastro-esophageal adenocarcinomas (GEAs) are a distinct subtype characterized by high immunotherapy sensitivity and better outcomes than MMR proficient counterparts. dMMR confers a hypermutator-phenotype that theoretically enables high evolvability but this has not been investigated by multi-region exome sequencing (MSeq). MSeq of four dMMR GEAs revealed extreme intratumor heterogeneity (ITH) (average: 1639 heterogeneous mutations/tumor), exceeding ITH in other solid tumor types >20-fold. Long phylogenetic trunks (average: 685 mutations/tumor) likely explain the exquisite sensitivity to checkpoint-inhibiting immunotherapies. Driver mutations in TP53, ACVR2A, ARID1A/B, dMMR- and WNT-pathway genes recurrently located to the phylogenetic trunk. The hypermutator-phenotype remained active during cancer progression. Subclonal and parallel driver evolution predominated in PIK3CA, epigenetic regulator and immune evasion genes. Chromosomal instability evolved late in carcinogenesis or during cancer progression. Extreme ITH and subclonal driver evolution support high evolvability of dMMR GEAs. Truncal ARID1A mutations may offer novel therapeutic opportunities.

| EGAS00001003434 | EGA

GENOMIC INSTABILITY IN MISMATCH REPAIR DEFICIENT COLORECTAL CANCER

Project description:Here we performed whole exome sequencing on a series of 47 mismatch repair (MMR) deficient colorectal cancers (CRC) in order to identified key events in tumoral initiation and progression

| EGAS00001002477 | EGA

Frequent germline mutations and somatic repeat instability in DNA mismatch-repair-deficient Caenorhabditis elegans.

Project description: Not available

| S-EPMC1462132 | biostudies-other